Table 5 Relationship between Quality of Life (QOL) and productivity measures and sncontinence status a
Variables | Incontinence statusb | |||
|---|---|---|---|---|
Continent | Incontinent | |||
(n = 78) | (n = 235) | |||
General QOL | EQ-5D utility score‡‡ | USA* | 0.82 (0.22) | 0.68 (0.24) |
Europe | 0.73 (0.22) | 0.70 (0.22) | ||
Total | 0.75 (0.22) | 0.70 (0.22) | ||
Disease-specific QOL | I-QOL score‡‡ | USA** | 72 (19) | 57 (23) |
Europe*** | 59 (17) | 50 (19) | ||
Total*** | 63 (19) | 52 (20) | ||
OAB-q: Symptom severity‡‡ | USA* | 37 (19) | 49 (19) | |
Europe*** | 41 (20) | 56 (18) | ||
Total*** | 40 (20) | 54 (19) | ||
OAB-q: HRQL total‡‡ | USA*** | 79 (15) | 62 (23) | |
Europe | 63 (19) | 57 (19) | ||
Total** | 67 (20) | 58 (20) | ||
Productivity | WPAI activity impairment‡‡ | USA | 34 (26) | 46 (28) |
Europe | 48 (22) | 55 (25) | ||
Total* | 44 (24) | 52 (26) | ||
WPAI overall impairment | USA | 53 (32) | 32 (19) | |
(among patients on paid employment: n (continent) = 19, n(incontinent) = 45)‡‡ | Europe | 49 (22) | 50 (28) | |
Total | 50 (23) | 43 (26) | ||
WPAI impairment while working (among patients on paid employment: n (continent) = 19, n(incontinent) = 45)‡‡ | USA | 38 (33) | 33 (18) | |
Europe | 39 (22) | 46 (24) | ||
Total | 39 (24) | 42 (23) | ||
WPAI work time miss (among patients on paid employment: n (continent) = 19, n(incontinent) = 45)‡‡ | USA | 15 (26) | 1 (2) | |
Europe | 8 (13) | 12 (21) | ||
Total | 10 (15) | 8 (18) | ||
Proportion of patients on paid employment‡∆ | USA | 5 (23.8%) | 15 (24.2%) | |
Europe | 14 (24.6%) | 30 (17.9%) | ||
Total | 19 (24.4%) | 45 (19.6%) | ||